
Opinion|Videos|May 8, 2024
Integrating New PAH Therapies into Clinical Practice
An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.
Advertisement
Video content above is prompted by the following questions:
- Sotatercept, a new treatment for PAH, recently received FDA approval in April 2024. How do you see this new therapy, as well as other emerging pulmonary arterial hypertension (PAH) treatments, fitting into the current treatment paradigm for PAH?
- What key factors should guide clinicians in determining the appropriate use of these new therapies in clinical practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5